anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The utility model discloses a face pack for preventing and relieving the formation and the deepening of furrows between eyebrows on the face. The face pack is a plane rubber board formed by that a layer of colloid film is coated on a thin board to form a rubber surface. The face pack comprises main forming materials of the thin board, a colloid and a rubber surface protecting film, wherein, the board is the thin board which has a certain plane supporting force; when the board with good flexibility is adopted, the face pack can be used for other needed parts on the face; the colloid has the advantages of nontoxicity, nonirritant, proper viscosit and no skin injury; the colloid with the functions of skin protection and treatment can be adopted. After the face pack is adopted, when an involuntary frowning action is generated, the position between the eyebrows is fixed by the plane supporting force of the face pack, and consequently, the formation and the deepening of the furrows shaped like the Chinese character Chuan between the eyebrows are prevented and relieved. The shape of the face pack is random, the proper shape and the proper size of the face pack can be adopted, and the proper shape of the face pack can be cut by a user to use. The face pack has the advantages of simple structure, easy manufacture, safe use, convenience, efficiency, low cost, and convenient popularization and application.
Personal Information Form (PIF) and Beck Anxiety Scale (BAS) were administered to the Reiki group through face-to-face interviews. Then, blood was taken for biochemical blood and cortisol findings and ECG was taken. After the pre-tests of the patients were completed, the application was made under the guidance of a researcher with a Usui Reiki Master \& Teacher degree and by a researcher with Reiki II training. In accordance with the Reiki Practice Protocol, an empty and silent room was selected in the hospital. Reiki was applied one-on-one to energy centers (crown chakra, forehead chakra, throat chakra, heart chakra, solar plexus, sacral region, root chakra, knees, ankle and feet) for 30 minutes. On the second day, 30 minutes of distant Reiki was applied. BAS was administered 1 week later; ECG was taken and biochemistry blood was taken.
1. Technical Result Increase in efficiency of treatment of restenosis, cancer, psoriasis and viral infections.         2. Essence Pharmaceutical compositions comprising the compounds of the formula wherein the mentioned radicals are defined in the specification or their pharmaceutically acceptable salt, ester, amid and prodrug and the compounds having HMG CoA reductases inhibiting activity.        3. Field of Application Medicine.               Tables: 1
Control Group Teacher education as usual. These participants will participate in teacher training (Neuroscience for Education - Neuro Educa). The Neuro-Educa will be held once a week for 8-weeks, two-hour meetings (16.0-h total).
A composition for X-ray visualization of body organs &c contains at least 50 per cent of a sodium lead chelate of a synthetic polyamino polycarboxylic acid, e.g. ethylene- or propylene-diamine tetracetic acid, trimethylenediamine tetracetic acid, 1,2-diaminocyclohexane tetracetic acid, mono(hydroxyethyl)ethylene diamine triacetic acid, monobenzylethylene diamine triacetic acid.  Disodium lead ethylene diamine tetracetic acid is prepared by adding a small molar excess lead carbonate to an aqueous slurry of the acid and then adjusting the pH to 7.3 by sodium hydroxide solution, the excess lead precipitating being removed by filtration.ALSO:A composition for X-ray visualization of body organs &c., contains at least 50 per cent of a sodium lead chelate of a synthetic polyamino polycarboxylic acid, e.g. ethylene- or propylene - diamino tetraacetic acid, trimethylenediamine tetraacetic acid, 1,2-diamino-cyclohexane tetraacetic acid, mono-(hydroxyethyl)ethylene diamine triacetic acid. The sodium calcium chelates of these acids may also be present in the proportion of 1 : 1-20 of the sodium lead chelate.  Aqueous solutions of pH 7.3-7.5 containing up to 15 per cent lead are suitably employed.  The preparation of disodium lead ethylenediamine tetraacetic acid is described (see Group IV (b)).
The study is aimed to compare clinical superiority of ultra fast-track versus conventional early postoperative extubation in patients undergoing cardiac surgery in our center. The estimated sample size is 382 patients. They will be randomized 1:1 to any of the two arms of the study (ultra fast-track vs. fast-track). The randomization will be stratified according the type of surgery performed. The period of recruitment will start in January 2023 and is supposed to finish by December 2024 or earlier. The main outcomes of the study will be measured 1 year after the procedure.
The present invention discloses a medicinal water-soluble microcapsule. A mother pill is prepared by that adhesive is sprayed to the mixture of water-soluble starch and lactose powder which are mixed according to the ratio of 1:1. The adhesive is an aqueous solution of water-soluble starch and sodium carboxymethylcellulose, wherein the concentration of the water-soluble starch is from 20 to 30%, the concentration of the sodium carboxymethylcellulose is from 1 to 3%, and the coating is a hydroxypropyl methylcellulose alcohol solution with the concentration of 5 to 8%. The production method comprises the steps that the mixture of the water-soluble starch and the lactose powder which are mixed according to the ratio of 1:1 is placed on a fluidized bed, and the adhesive is cut and sprayed on the water-soluble starch to prepare the mother pill; medicinal materials are cut and sprayed on the mother pill to prepare a medicine loading layer; 10 to 80% of alcohol as a solvent is prepared into the hydroxypropyl methylcellulose alcohol solution with the concentration of 5 to 8%, and then cut and sprayed on the medicine loading layer. The microcapsule can be quickly and completely dissolved in the stomach, the pharmacodynamic action can be performed as soon as possible, and the medicinal utilization rate is high. The production technology ensures that the mother pill has regular shapes and uniform sizes, and the thicknesses of the medicine loading layer and the coating layer are uniform. Medicines can be furthest loaded, and the coating materials can be saved.
Nutritional deficiency of iron in 30-70% of young children in different communities in India is well documented and has proved challenging to eradicate both in India and globally. Less is known about zinc deficiency, but zinc and iron are generally present in the same foods and there is also growing evidence for the public health importance of zinc deficiency in young children on a global basis. In populations that depend primarily on plant-based foods, biofortification of major food staples by traditional selective plant breeding procedures offers an attractive strategy for preventing iron and zinc deficiency in all age groups. Pearl millet, a major food staple in several areas of India, has both naturally relatively high concentrations of iron and zinc with demonstrated potential to increase these levels further with plant breeding. Before embarking on complex, costly efficacy, effectiveness studies of the potential health benefits of this biofortified grain, the objective of this project is to determine the extent to which iron and zinc absorption is increased in very young children who consume pearl millet as the primary grain and major food staple. This is a short term, cross-sectional double-blinded study in which the test or control pearl millet is fed for a total of 9 days. Primary outcome measures are the increases in iron and zinc absorption over a two-day period. Test meals will be labeled with a zinc stable isotope on Day 8 and an iron stable isotope on Days 8 and 9 during which days participants and their mothers will stay in their community health center. Food intake will be weighed and duplicate diets obtained. Percentage iron absorption will be determined from erythrocyte enrichment on Day 23. Fractional zinc absorption will be measured from urine enrichment with orally and intravenously administered zinc isotopes from timed samples collected on Days 12-15. Daily absorption of these minerals will be determined. Increases in intake and absorption of these minerals (mg/d) will be evaluated with respect to estimated dietary and physiologic requirements.
This is a randomized, non-blinded, multicenter treatment trial to demonstrate and compare the efficacy of esomeprazole and fluticasone in the treatment of eosinophilic esophagitis.

Following the initial diagnostic EGD with four quadrant biopsy, serum eosinophil count and serum IgE levels will be measured. Patients will undergo 24 hour pH study to determine the incidence of reflux in this population. Clinical assessment will be performed with validated questionnaires quantifying dysphagia, GERD, and allergy/atopy. Patients will be randomized to 8 weeks of either esomeprazole versus swallowed aerosolized fluticasone. After 8 weeks of therapy, upper endoscopy will again be performed. Eosinophils per high power field will be quantified, and biopsies will be stained for major basic protein. Dysphagia, GERD, and allergy/atopy questionnaires will be repeated, as will serum eosinophil counts and IgE measurements.
PCT No. PCT/SE94/00010 Sec. 371 Date Oct. 16, 1995 Sec. 102(e) Date Oct. 16, 1995 PCT Filed Jan. 10, 1994 PCT Pub. No. WO94/15584 PCT Pub. Date Jul. 21, 1994The invention relates to solutions containing IGF-1 or any functional analogue thereof in which pH is 5.5 to 6.5, preferably 5.7 to 6.2. The amount of phosphate as buffer substance should be in a concentration of less than 50 mmol/L Preferably the formulation is an aqueous solution of IGF-1 and phosphate as buffer substance in a concentration of 5 to 50 mmole or more preferably 5-20 mmol/L, e.g. 10 mmol/L. The solution should be isotonic. The solution gives a reduced pain upon subcutaneous injection. The invention also relates to a process for preparation of the formulation by mixing IGF-1 or any functional analogue thereof with a buffer substance giving pH 5.5 to 6.5 and an isotonic agent. It also relates to a method for treatment of a patient in need of IGF-1 or any functional analogue thereof by administering the claimed formulation.
Biphasic insulin aspart 30 administered once daily for 16 weeks. If HbA1c is higher than 7.0 % after 16 weeks of treatment, dose is increased to twice daily for another 16 weeks. If HbA1c is higher than 7.0 % after 32 weeks of treatment, dose is increased to three times daily until week 48 (end of trial).
Burosumab, which is FDA-approved for X-linked hypophosphatemic rickets, will be given monthly, for a total of 12 months and titrated to achieve a target fasting serum phosphorus level within normal range for age. The chosen starting dose of burosumab will be 0.3 mg/kg given SQ Q4W. The maximum dose allowed in this protocol is 2.0 mg/kg. Burosumab will be administered via subcutaneous (SC) route.
OBJECTIVES: I. Compare early mortality, survival, and disease free survival in patients with node positive stage II or IIIA breast cancer treated with busulfan, melphalan, and thiotepa versus cyclophosphamide, thiotepa, and carboplatin followed by autologous peripheral blood stem cell transplantation. II. Compare the toxicity of these 2 regimens in this patient population.

OUTLINE: This is a randomized study. Patients are stratified according to stage of disease (stage II vs stage IIIA), lymph node status (at least 10 positive nodes vs less than 10 positive nodes), and hormone receptor status (estrogen receptor positive or progesterone receptor positive vs estrogen receptor negative or progesterone receptor negative). All patients initially receive mobilization chemotherapy with cyclophosphamide IV over 1-2 hours on day 1 and paclitaxel IV over 4 hours on day 2. Beginning on day 4, patients receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously each day until the final day of leukapheresis. When blood counts recover, peripheral blood stem cells (PBSC) are harvested. Patients are randomized to 1 of 2 high dose chemotherapy regimens 28-45 days after the last dose of mobilization chemotherapy. Arm I: Patients receive oral busulfan every 6 hours on days -8 to -6, melphalan IV over 30-60 minutes on days -5 and -4, and thiotepa IV over 2 hours on days -3 and -2. PBSC are reinfused on day 0. Arm II: Patients receive cyclophosphamide, thiotepa, and carboplatin by continuous IV infusion over 24 hours on days -7, to -4. PBSC are reinfused on day 0. Beginning 4-6 weeks after the last dose of chemotherapy, patients in both arms receive local radiotherapy 5 days each week for 5 weeks. Patients also receive oral tamoxifen (or equivalent antiestrogen therapy) daily for 5 years if they are estrogen or progesterone receptor positive, postmenopausal, or age 50 and over and perimenopausal. Patients are followed every 3 months for 2 years and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 280 patients (140 per treatment arm) will be accrued for this study over 3 years.
Polygenic risk scores (PRS) aim to predict a trait from genetic information, relying on common genetic variants with low to medium effect sizes. As genotype data are high-dimensional in nature, it is crucial to develop methods that can be applied to large-scale data (large  n $$ n $$  and large  p $$ p $$  ). Many PRS tools aggregate univariate summary statistics from genome-wide association studies into a single score. Recent advancements allow simultaneous modeling of variant effects from individual-level genotype data. In this context, we introduced snpboost, an algorithm that applies statistical boosting on individual-level genotype data to estimate PRS via multivariable regression models. By processing variants iteratively in batches, snpboost can deal with large-scale cohort data. Having solved the technical obstacles due to data dimensionality, the methodological scope can now be broadened-focusing on key objectives for the clinical application of PRS. Similar to most methods in this context, snpboost has, so far, been restricted to quantitative and binary traits. Now, we incorporate more advanced alternatives-targeted to the particular aim and outcome. Adapting the loss function extends the snpboost framework to further data situations such as time-to-event and count data. Furthermore, alternative loss functions for continuous outcomes allow us to focus not only on the mean of the conditional distribution but also on other aspects that may be more helpful in the risk stratification of individual patients and can quantify prediction uncertainty, for example, median or quantile regression. This work enhances PRS fitting across multiple model classes previously unfeasible for this data type.
Coronavirus disease 2019 (COVID-19) is associated with enlarged luminal areas of large conducting airways. In 10-30% of patients with acute COVID-19 infection, symptoms persist for more than 4 wk (referred to as post-acute sequelae of COVID 19, or PASC), and it is unknown if airway changes are associated with this persistence. Thus, we aim to investigate whether luminal area of large conducting airways is different between patients with PASC and COVID-19 and healthy controls. In this retrospective case-control study, 75 patients with PASC (48 females) were age-, height-, and sex-matched to 75 patients with COVID-19 and 75 healthy controls. Using three-dimensional digital reconstruction from computed tomography imaging, we measured luminal areas of seven conducting airways, including trachea, right and left main bronchi, bronchus intermediate, right and left upper lobe, and left lower lobe bronchi. Kruskal-Wallis H test was used to compare measurements between the three groups, as appropriate. Airway luminal areas between COVID-19 and PASC groups were not different (all, P > 0.66). There were no group differences in airway luminal area (PASC vs. control) for trachea and right main bronchus. However, in the remaining five airways, airway luminal areas were 12-39% larger among patients with PASC than in controls (all, P < 0.05). Patients diagnosed with COVID-19 and PASC have greater airway luminal area in most large conducting airways compared with healthy controls. No differences in luminal area between patients with COVID-19 and PASC suggest persistence of changes or insufficient time for reversal of changes.NEW & NOTEWORTHY Three-dimensional reconstruction of airways has shown increased luminal area in patients with COVID-19 and post-acute sequelae of COVID-19 when compared with healthy controls. These findings suggest the role of large conducting airways in the pathogenesis of post-acute sequelae of COVID 19.
Protein arginine methyltransferase (PRMT) 2 catalyzes the methylation of arginine residues in histones. Depression is associated with histone methylation; however, more comprehensive research is needed on how PRMT2 regulates depression. The present study aimed to investigate the effects and possible mechanism(s) of PRMT2 overexpression on depression-like behavior induced by chronic unpredictable mild stress (CUMS) in rats, and whether lentivirus-mediated PRMT2 overexpression in the hippocampus suppresses depression-like behavior. Furthermore, the PRMT2 inhibitor MS023 was administered to the animals to investigate whether the antidepressant effect of PRMT2 overexpression could be reversed. Behavioral experiments were performed to detect depression-like behavior in rats. Western blotting was used to determine protein expression levels of PRMT2, histone H3R8 asymmetric dimethylation (H3R8me2a), inducible nitric oxide synthase (iNOS), and arginase 1 (Arg1) in rat hippocampal tissues. Hippocampal microglia and PRMT2 were stained using immunofluorescence techniques. Enzyme-linked immunosorbent assay was used to determine the levels of various inflammatory factors in rat hippocampal tissue. Results of analysis revealed that PRMT2 overexpression in the hippocampus exerted an antidepressant effect. PRMT2 overexpression in the hippocampus reduced the proportion of activated microglia in the hippocampus, upregulated Arg1 and H3R8me2a expression, and downregulated iNOS expression. PRMT2 overexpression in the hippocampus inhibited the release of pro-inflammatory factors and promoted the release of anti-inflammatory factors. In summary, PRMT2 overexpression in the hippocampus promoted the conversion of microglia from the M1 to M2 type, resulting in an antidepressant effect. These results suggest that PRMT2 may be a potential therapeutic target to prevent and treat depression.
PURPOSE:To obtain the title kinase catalysing phosphoric acid modification of tau-protein, by preparing microtubular protein from a crude extract from the brain followed by ammonium sulfate fractionation, phosphocellulose column chromatography, etc. CONSTITUTION:A microtubular protein is prepared from an extract from e.g., the rat brain. Thence, the objective tau-protein kinase is separated and purified by combination of such operations as ammonium sulfate fractionation, phosphocellulose column chromatography and gel permeation. This tau-protein kinase acts as follows: the serine in tau-protein is phosphoric acid-modified with ATP as the phosphoric acid donor to introduce 4-5 phosphoric acid residues per molecule of the tau-protein. Optimum pH...6.5 (in the absence of tuberins) optimum pH...6.0 (in the presence of tuberins) optimum temperature...37 deg.C. This tau-protein kinase may be involved in the promotion of aging, thus being expected to be applied on the study and diagnosis of Alzheimer's disease.
PCT No. PCT/GB92/01324 Sec. 371 Date Jan. 26, 1994 Sec. 102(e) Date Jan. 26, 1994 PCT Filed Jul. 20, 1992 PCT Pub. No. WO93/02186 PCT Pub. Date Feb. 4, 1993.A cocaine esterase has been isolated from a strain of the bacteria Pseudomonas maltophilta, The cocaine esterase catalyses the debenzoylation of cocaine, This reaction may be used in the detection of cocaine. The enzyme may be incorporated into sensors for this purpose. The cocaine esterase is preferably obtainable from Pseudomonas sp. NCIMB 40427. It catalyzes the debenzoylation of cocaine, has a molecular weight in the unaggregated form of about 120,000 daltons as determined by gel filtration, has esterase activity specifically at the benzoate ester linkage of cocaine, separates at a major band of Rf about 0.2 on PAGE in its aggregated form, and it is completely inhibited by 1 mM phenylmethylsulphonyl fluoride but ineffectively inhibited by 1 mM eserine, each determined at 30 DEG  C. with respect to 2 mM cocaine as substrate.
PURPOSE:A hypotensor containing a dipeptide derivative, its salt or a compound convertible thereto in the body. CONSTITUTION:The objective hypotensor contains the compound of formula, its salt and/or a compound convertible thereto in the body (e.g. benzyl ester, methyl ester, ethyl ester, etc.). It is applied orally in the form of tablet, capsule, elixir, etc., or parenterally in the form of aseptic solution or suspension. Dose: 1-2,000mg/day. It can be used in combination with other diuretic or antihypertensive. In the case of combined use, the dose of each component is selected to the level permissible to be applied daily. The agent has high safety and can be synthesized easily.
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer and its prognosis remains poor. Although growing numbers of studies have verified the involvement of circular RNAs (circRNAs) in various cancer types, their specific functions in ICC remain elusive. Herein, a circRNA, circUGP2 is identified by circRNA sequencing, which is downregulated in ICC tissues and correlated with patients' prognosis. Moreover, circUGP2 overexpression suppresses tumor progression in vitro and in vivo. Mechanistically, circUGP2 functions as a transcriptional co-activator of PURB over the expression of ADGRB1. It can also upregulate ADGRB1 expression by sponging miR-3191-5p. As a result, ADGRB1 prevents MDM2-mediated p53 polyubiquitination and thereby activates p53 signaling to inhibit ICC progression. Based on these findings, circUGP2 plasmid is encapsulated into a lipid nanoparticle (LNP) system, which has successfully targeted tumor site and shows superior anti-tumor effects. In summary, the present study has identified the role of circUGP2 as a tumor suppressor in ICC through regulating ADGRB1/p53 axis, and the application of LNP provides a promising translational strategy for ICC treatment.
FIELD: chemical-pharmaceutical industry. SUBSTANCE: rhizomes and roots of Eleutherococcus are extracted with 24-26% alcohol for 1,5-2 h at 50-60 C. Extract is decanted and extracted repeatedly, under the same conditions. Then extracts are combined, filtered, condensed and dried. Result: dry extract is obtained. EFFECT: improved method of bioactive additive preparing. 3 cl
Therapeutic compositions (see Division A5) may be formulated in aerosol packages and comprise an inert propellant, e.g. fluorinated hydrocarbons such as dichlorodifluoromethane, nitrogen and carbon dioxide.ALSO:A therapeutic composition for the treatment of anal and perianal disorders comprises 0.25 to 5.0% by weight of 4-[3-(p-butoxyphenoxy) propyl] morpholine or pharmaceutically acceptable addition salts thereof, e.g. the hydrochloride, as an anaesthetic agent; 0.05 to 2.0% by weight of allantoin or aluminium salts thereof, e.g. aluminium chlorhydroxy allantoinate, as a healing agent; 0.01 to 0.5% by weight of a surface active agent comprising a quaternary ammonium salt, e.g. cetylpyridinium chloride; 10 to 75% by weight of an astringent cooling agent, e.g. hamamelio water; blended with a pharmaceutically acceptable water-soluble vehicle e.g. water, alcohol, gells, lotions or creams.  Other additives include preservatives, antioxidants, buffering agents, solvents and perfumes. The compositions, which are applied topically may be in the form of gells, lotions, ointments or creams, which may be applied either directly or via a tissue from an aerosol container containing the composition and a propellant or from a pre-moistened tissue.